Compare Atmos Energy Corporation (ATO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Incyte Corporation — how do they compare? Atmos Energy Corporation trades at $169.77 (market cap $28.59B), while Incyte Corporation trades at $120.8 (market cap $24.54B). The key difference: Atmos Energy Corporation is the larger of the two by market cap, and Atmos Energy Corporation pays a 2.36% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ATO | INCY | |
|---|---|---|
Market Cap | $28.59B | $24.54B |
Sector | Utilities | Health |
52-Week High | $192.25 | $129.93 |
52-Week Low | $162.44 | $81.61 |
Enterprise Value | $38.40B | $20.04B |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $169.68, up 1.05% today, with a bearish technical signal but strong fundamentals including a 28.5% net income margin and consistent dividend payments. Recent Q3 2026 earnings beat estimates with EPS of $1.43 versus $1.35 expected, and the company reaffirmed fiscal 2026 guidance. The stock shows neutral oscillators but bearish moving averages, with key support at $168.
The outlook is mixed: analyst consensus is a Buy with a $190.57 price target, but technical indicators suggest near-term caution. Risks include high capital expenditures impacting cash flow and interest rate sensitivity. Upside potential hinges on execution of rate hikes and infrastructure investments, while downside risks involve regulatory changes and economic slowdowns.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
